SOUTH SAN FRANCISCO, Calif., Oct. 8, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc.
(Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage, biopharmaceutical company
developing novel therapeutics to treat cancer and eye diseases, announced today
that its Chief Executive Officer, John A. Kollins, has resigned from his
position with the Company and as a member of the Board of Directors in order to
pursue other interests. Dr. Peter Langecker, M.D., Ph.D., Executive Vice
President and Chief Development Officer, will serve as Interim Chief Executive
Officer while the Company conducts a search for a permanent replacement for Mr.
Kollins.
William N. Shiebler, Chairman of OXiGENE's Board of Directors, commented, "On
behalf of the Board of Directors, I want to thank John Kollins for his
dedicated service and contributions to OXiGENE. We wish him success in his new
endeavors."
About OXiGENE
OXiGENE is a clinical-stage biopharmaceutical company developing novel
therapeutics to treat cancer and eye diseases. The company's major focus is
developing vascular disrupting agents (VDAs) that selectively disrupt abnormal
blood vessels associated with solid tumor progression and visual impairment.
OXiGENE is dedicated to leveraging its intellectual property and therapeutic
development expertise to bring life-extending and life-enhancing medicines to
patients.
The OXiGENE, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=4969
CONTACT: OXiGENE, Inc.
Investor and Media Contact:
Michelle Edwards, Investor Relations
650-635-7006
medwards@oxigene.com
Oxigene Announces Management Changes
| Source: Oxigene, Inc.